Publications

. Highly Sensitive UPLC-MS/MS Method for the Quantification of Paromomycin in Human Plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020.

PDF DOI PubMed

. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. Clinical Pharmacology & Therapeutics, 2020.

PDF DOI PubMed

. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients With Solid Tumors. Clinical Pharmacokinetics, 2020.

PDF DOI PubMed

. Clinical Trial Simulation to Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation. CPT Pharmacometrics & Systems Pharmacology, 2020.

PDF DOI PubMed

. Exposure to Docetaxel in the Elderly Patient Population: A Population Pharmacokinetic Study. Pharmaceutical Research, 2019.

PDF DOI PubMed

. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. Pharmaceutical Research, 2019.

PDF DOI PubMed

. Quackery at WHO: A Chinese Affair. Skeptical Inquirer, 2019.

PDF Web

. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Advances, 2019.

PDF DOI PubMed

. A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Pharmacokinetics, 2019.

PDF DOI PubMed

. Systematic review of host-mediated activity of miltefosine in leishmaniasis through immunomodulation. Antimicrobial Agents and Chemotherapy, 2019.

PDF DOI PubMed

. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Clinical Pharmacokinetics, 2019.

PDF DOI PubMed

. Pharmacokinetics, safety and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase-II clinical trial. Clinical Infectious Diseases, 2019.

PDF DOI PubMed

. Hoe China de WHO misbruikt voor zijn eigen agenda. Medisch Contact, 2019.

PDF Web

. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. Pharmaceutical Research, 2019.

PDF DOI PubMed

. Safe mass drug administration for neglected tropical diseases. The Lancet Global Health, 2018.

PDF DOI PubMed

. Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2018.

PDF DOI PubMed

. Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships. Journal of Antimicrobial Chemotherapy, 2018.

PDF DOI PubMed

. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. Journal of Pharmacokinetics and Pharmacodynamics, 2018.

PDF DOI PubMed

. Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2018.

PDF DOI PubMed

. From Bench to Bedside: Development and Optimization of Clinical Therapies for Visceral Leishmaniasis. In: Drug Discovery for Leishmaniasis, The Royal Society of Chemistry, pp. 37–54, 2018.

PDF DOI Web

. Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. Clinical Pharmacokinetics, 2018.

PDF DOI PubMed

. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. Journal of Antimicrobial Chemotherapy, 2017.

PDF DOI PubMed

. Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples. Journal of Pharmaceutical and Biomedical Analysis, 2017.

PDF DOI PubMed

. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2017.

PDF DOI PubMed

. Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients. Frontiers in Immunology, 2017.

PDF DOI PubMed

. Gebruik van niet-reguliere behandelwijzen voor kanker naast reguliere behandeling. In: Leerboek Oncologie, Bohn Stafleu van Loghum, 2017.

DOI Web

. Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS. Journal of Biological Chemistry, 2016.

PDF DOI PubMed

. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection. Antimicrobial Agents and Chemotherapy, 2016.

PDF DOI PubMed

. Treatment of visceral leishmaniasis: pitfalls and stewardship. The Lancet Infectious Diseases, 2016.

PDF DOI PubMed

. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Tropical Medicine & International Health:, 2016.

PDF DOI PubMed

. Poverty-Related Diseases College: a virtual African-European network to build research capacity. BMJ Global Health, 2016.

PDF DOI PubMed

. Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 2016.

PDF DOI PubMed

. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLOS Neglected Tropical Diseases, 2016.

PDF DOI PubMed

. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clinical Pharmacokinetics, 2016.

PDF DOI PubMed

. Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain. Parasitology Research, 2015.

PDF DOI PubMed

. Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 2015.

PDF DOI PubMed

. Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. British Journal of Clinical Pharmacology, 2015.

PDF DOI PubMed

. WHO's Strategy on Traditional and Complementary Medicine. Scientific Inquirer, 2015.

PDF Web

. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrobial Agents and Chemotherapy, 2015.

PDF DOI PubMed

. Different liposomal amphotericin B formulations for visceral leishmaniasis. The Lancet Global Health, 2014.

PDF DOI PubMed

. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. Journal of Infectious Diseases, 2014.

PDF DOI PubMed

. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. Journal of Travel Medicine, 2014.

PubMed

. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLOS Neglected Tropical Diseases, 2014.

PDF DOI PubMed

. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. PloS One, 2014.

PDF DOI PubMed

. Reply to Arya and Agarwal. Clinical Infectious Diseases, 2013.

PDF DOI PubMed

. The global impact of Indian generics on access to health. Indian Journal of Medical Ethics, 2013.

PDF DOI PubMed

. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases, 2013.

PDF DOI PubMed

. Please, let not Western quackery replace traditional medicine in Africa. Tropical Medicine & International Health:, 2013.

PDF DOI PubMed

. Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. Tropical Medicine & International Health:, 2013.

PDF DOI PubMed

. [Concomitant use of proton pump inhibitors and systemic corticosteroids]. Nederlands Tijdschrift Voor Geneeskunde, 2013.

PDF PubMed

. Commentary: Substandard medicines are the priority for neglected tropical diseases. BMJ, 2012.

PDF DOI PubMed

. Universal access to quality medicines: prioritisation of a-priori solutions. The Lancet Infectious Diseases, 2012.

PDF DOI PubMed

. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy, 2012.

PDF DOI PubMed

. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. Journal of Antimicrobial Chemotherapy, 2012.

PDF DOI PubMed

. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012.

PDF DOI PubMed

. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 2012.

PDF DOI PubMed

. Characterization and identification of suspected counterfeit miltefosine capsules. The Analyst, 2012.

PDF DOI PubMed

. A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal. PLOS Neglected Tropical Diseases, 2012.

PDF DOI PubMed

. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLOS Neglected Tropical Diseases, 2011.

PDF DOI PubMed

. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials, 2011.

PDF DOI PubMed

. Severe encephalopathy and polyneuropathy induced by dichloroacetate. Journal of Neurology, 2010.

PDF DOI PubMed

. Comment on: Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010.

DOI PubMed

. China vaart wel bij kruidenexport. Medisch Contact, 2009.

PDF Web

. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrobial Agents and Chemotherapy, 2008.

PDF DOI PubMed

. Pentamidine dosage: a base/salt confusion. PLOS Neglected Tropical Diseases, 2008.

PDF DOI PubMed

. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 2008.

PDF DOI PubMed

. [Miltefosine: a new remedy for leishmaniasis]. Nederlands Tijdschrift Voor Geneeskunde, 2006.

PDF PubMed